CriticalClass Ia antiarrhythmic with antimuscarinic activity×Antianginal – late sodium current inhibitor
Updated · Methodology
Mechanism
Ranolazine blocks the IKr potassium current and prolongs the heart-rate-corrected QT interval (QTc) in a concentration-dependent way (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). Disopyramide is a class Ia antiarrhythmic (disopyramide SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The ranolazine SmPC lists it among QTc-prolonging antiarrhythmics that carry a theoretical risk of a pharmacodynamic interaction and ventricular arrhythmias with ranolazine (EMA). Disopyramide itself prolongs the QT interval and widens the QRS complex. Like all antiarrhythmics, it can cause ventricular tachycardia, ventricular fibrillation and torsade de pointes (AEMPS). CYP3A metabolises disopyramide, and inhibitors of this enzyme may raise its levels (AEMPS). Ranolazine is a weak CYP3A4 inhibitor (EMA), but the documents give no figures for this pair.
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). At toxic plasma levels of disopyramide, marked QT prolongation warns of torsade de pointes, which can cause repeated fainting. The ECG shows QRS widening and atrioventricular block of varying degree (disopyramide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, overdose section). Arrhythmias with disopyramide are more likely with low potassium, severe structural heart disease, a prolonged QT interval and other antiarrhythmics (AEMPS). Warning signs of a possible arrhythmia are feeling faint or lightheaded and an irregular or fast heartbeat (ranolazine label, US Food and Drug Administration, FDA). Higher ranolazine levels make dizziness and nausea more likely (ranolazine SmPC, European Medicines Agency, EMA).
Management
The combination is contraindicated. The European ranolazine summary of product characteristics (SmPC) contraindicates ranolazine with class Ia and class III antiarrhythmics other than amiodarone (ranolazine SmPC, European Medicines Agency, EMA). The disopyramide SmPC classifies disopyramide as class Ia (disopyramide SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish disopyramide SmPC contraindicates disopyramide with other antiarrhythmics and with drugs that may cause ventricular arrhythmias, especially torsade de pointes, but its lists do not name ranolazine (AEMPS). The US ranolazine label is milder than the European SmPC: it has no contraindication and only notes limited experience with other QT-prolonging drugs (ranolazine label, US Food and Drug Administration, FDA). Disopyramide is contraindicated in pre-existing long QT. During treatment, monitor the QT interval and the QRS complex on the electrocardiogram (ECG), and stop disopyramide if they lengthen by more than 25% (AEMPS). Monitor blood potassium and correct it if it is out of range, because potassium imbalance can trigger arrhythmia (AEMPS). Start disopyramide for life-threatening arrhythmias in hospital (AEMPS). Use ranolazine with caution in congenital or familial long QT syndrome and known acquired QT prolongation (EMA). The documents give no interval between stopping one drug and starting the other.
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Ranolazine extended-release tablets (Zydus Lifesciences) – prescribing information (2026)– FDA label, Zydus Lifesciences, DailyMed setid d74f3dea-7357-4e9a-be9a-2f498a44108a, version 5, 09/2026, sections 2.2, 4, 5.1, 7.1 and 7.2
- AEMPS: Ficha técnica: Disopiramida (nº registro 52549), sección 4.5 (2025)– AEMPS, CIMA, nº registro 52549 (Dicorynan), revisión 03/2025, secciones 4.3, 4.4 y 4.5
- FDA: Norpace (disopyramide) prescribing information (2026)– DailyMed setid e2aa1642-d262-4520-bc6a-9fd3ad795677, revisión 08/2026, Contraindications, Precautions – Drug Interactions
- EMA: Ficha técnica: Ranolazina (EU/1/08/462), sección 4.3 (2026)– EMA SmPC vía AEMPS CIMA, nº 08462001 (EU/1/08/462), secciones 4.3, 4.5 y 4.9, consultado 10/2026
- EMA: Ficha técnica: Ranolazina, Ranexa (EU/1/08/462), sección 4.4 (2026)– EMA, Ranexa 375 mg comprimidos de liberación prolongada (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 08462001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.1, 4.4 y 4.5